 | Up a level |
Journal Article
Borchmann, P., Goergen, H., Kobe, C., Fuchs, M., Greil, R., Zijlstra, J. M., Huettmann, A., Markova, J., Meissner, J., Feuring-Buske, M., Bentz, M., Dierlamm, J., Kuehnhardt, D., Lohri, A., Novak, U., Eichenauer, D., Eich, H., Baues, C., Stein, H., Diehl, V., Kuhnert, G., Dietlein, M. and Engert, A. (2017). TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP. Haematologica, 102. S. 24 - 26. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Borchmann, P., Kobe, C., Pluetschow, A., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Soekler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Huettmann, A., Wilhem, M., Zijlstra, J. M., Moccia, A., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Eich, H., Baues, C., Hallek, M., Diehl, V, Dietlein, M. and Engert, A. (2020). Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group. Oncol. Res. Treat., 43 (SUPPL 4). S. 32 - 33. BASEL: KARGER. ISSN 2296-5262
Broeckelmann, P., Goergen, H., Fuchs, M., Eich, H., Stein, H., Diehl, V., Borchmann, P. and Engert, A. (2015). Sources of Errors in the Staging of Hodgkin Lymphoma - An Analysis of the central Assessment of diagnostic Measures 5965 Patients of the German Hodgkin Study Group (GHSG). Internist, 56. S. 3 - 5. NEW YORK: SPRINGER. ISSN 1432-1289
Broeckelmann, P., Goergen, H., Fuchs, M., Eich, H., Stein, H., Diehl, V., Borchmann, P. and Engert, A. (2015). Sources of Errors in the Staging of Hodgkin Lymphoma - An Analysis of the central Assessment of diagnostic Measures 5965 Patients of the German Hodgkin Study Group (GHSG). Internist, 56. S. 3 - 5. NEW YORK: SPRINGER. ISSN 1432-1289
Engert, A., Eich, H. and Hoeffken, K. (2022). Hodgkin lymphoma The paradigm for the success of interdisciplinary clinical trials. Onkologie, 28 (10). S. 842 - 845. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234
Kreissl, S., Goergen, H., Kobe, C., Fuchs, M., Greil, R., Huettmann, A., Meissner, J., Feuring-Buske, M., Bentz, M., Dierlamm, J., Kuehnhardt, D., Lohri, A., Novak, U., Eichenauer, D., Eich, H., Baues, C., Stein, H., Diehl, V., Kuhnert, G., Dietlein, M., Engert, A. and Borchmann, P. (2017). Treatment reduction in patients with advanced-stage-Hodgkin-lymphoma and negative interim PET: final results of the international randomized phase 3 trial HD18 by the German Hodgkin Study Goup. Oncol. Res. Treat., 40. S. 201 - 202. BASEL: KARGER. ISSN 2296-5262
Kriz, J., Baues, C., Oertel, M., Engenhart-Cabillic, R., Herfarth, K., Lukas, P., Marnitz-Schulze, S., Schmidberger, H., Vordermark, D., Haverkamp, U., Engert, A. and Eich, H. (2018). First Results of Quality Control of Involved Node Radiotherapy within the HD17-Study of the German Hodgkin Study Group (GHSG). Strahlenther. Onkol., 194. S. S14 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X
Kriz, J., Engenhart-Cabillic, R., Haverkamp, U., Herfarth, K., Lukas, P., Schmidberger, H., Staar, S., Engert, A. and Eich, H. (2015). Establishment of a new Quality Assurance Program in Age of modern Radiotherapy as Part of the German Hodgkin Study Group. Strahlenther. Onkol., 191. S. S165 - 1. MUNICH: URBAN & VOGEL. ISSN 1439-099X
Kriz, J., Engenhart-Cabillic, R., Haverkamp, U., Herfarth, K. K., Lukas, P., Schmidberger, H., Staar, S., Engert, A. and Eich, H. (2015). Establishing a New Quality Assurance Program of Modern Radiation Therapy Within the German Hodgkin Study Group. Int. J. Radiat. Oncol. Biol. Phys., 93 (3). S. E454 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X
Kriz, J., Pluetschow, A., Engenhart-Cabillic, R., Herfarth, K., Lukas, P., Schmidberger, H., Staar, S., Haverkamp, U., Baues, C., Engert, A. and Eich, H. (2015). Analysis of the Quality Assurance Program of the Involved Field Radiotherapy within the HD13 and HD14 Study the German Hodgkin Study Group. Strahlenther. Onkol., 191. S. S10 - 2. MUNICH: URBAN & VOGEL. ISSN 1439-099X
Kriz, J., Pluetschow, A., Engenhart-Cabillic, R., Herfarth, K. K., Lukas, P., Schmidberger, H., Staar, S., Haverkamp, U., Baues, C., Engert, A. and Eich, H. (2015). Quality Assurance of Involved Field Radiation Therapy Within the HD13 and HD14 Trial (early stages) of the German Hodgkin Study Group. Int. J. Radiat. Oncol. Biol. Phys., 93 (3). S. E449 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X
Moustakis, C., Ernst, I., Kittel, C., Eich, H., Krieger, T., Duma, M., Oechsner, M., Ganswindt, U., Heinz, C., Alheit, H., Blank, H., Nestle, U., Wiehle, R., Kornhuber, C., Ostheimer, C., Petersen, C., Albers, D., Pollul, G., Baus, W. W., Altenstein, G., Blanck, O., Beckers, E., Sterzing, F., Kretschmer, M., Seegenschmiedt, H., Maass, T., Droege, S., Wolf, U., Schoeffler, J., Thiele, M., Ciernik, I. F., Ebrahimi, F. and Guckenberger, M. (2015). Results of the Planning Comparison Study SBRT of NSCLC. Int. J. Radiat. Oncol. Biol. Phys., 93 (3). S. E573 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X
Wendtner, C. -M., Delank, S. and Eich, H. (2010). Multimodality therapy concepts for soft tissue sarcomas. Internist, 51 (11). S. 1388 - 1396. NEW YORK: SPRINGER. ISSN 0020-9554